Remove 2005 Remove Food and Drug Administration Remove Healthcare Remove Side effects
article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

One of the aspects of radiopharmaceuticals that is often overlooked is how complicated it is to develop a new agent, in terms of the complexity of drug design to realise a therapeutic candidate and the implementation of the clinical evaluations. This is not an effective strategy.

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.

article thumbnail

Ep. 001 – John Mack Podcast Transcript

Pharma Marketing Network

You know, in November 2009, the FDA held a public hearing about the promotion of Food and Drug Administrative Related Regulated Medical Products, using the internet and social media tools. They would write up the presentations by physicians about drugs. So that was 2005. So, I didn’t look so bad. It’s a blog.

Media 52